

Mahajan, Vinay

From: Riemenschneider, Marion on behalf of Office, Vas Narasimhan (Gen)
Sent: Wednesday, February 22, 2017 2:31 PM
Subject: Important Organizational Announcement



Dear colleagues,

I'm very pleased to share two important appointments to our Global Drug Development (GDD) leadership team.

Effective March 1, 2017 **Samit Hirawat**, M.D., is appointed Global Head of Oncology Development. Samit has held this role ad interim since January 2, 2017 and has helped us maintain the momentum in advancing our exciting oncology pipeline. Samit will be a member of the Global Drug Development and Oncology leadership teams and report functionally to Bruno Strigini in the Oncology Division and operationally to me. Samit will also be a core member of the Novartis Innovation Management Board (IMB).

Samit brings a wealth of oncology experience to this role and has also been a key leader in our oncology business for the last 10 years. As one of our Global Program Heads in Oncology, Samit most recently led the successful development and regulatory submission for LEE011 – our breakthrough therapy for hormone receptor positive, HER2-negative advanced breast cancer. Samit joined Novartis Oncology Global Development in 2007 and has been in pivotal leadership roles advancing several cancer medicines including panobinostat, buparlisib, alpelisib and ribociclib. Prior to Novartis, Samit led clinical development programs in multiple indications at PTC Therapeutics and Pfizer/Pharmacia Corporation.

I am also pleased to announce that **Danny Bar Zohar**, M.D., has been appointed Global Head Neuroscience Development, effective April 1, 2017, reporting directly to me. Danny will join the Global Drug Development leadership team and will also co-lead the Neuroscience Franchise Leadership Team. Danny is currently Chief Scientific Officer for Novartis Pharma Italy S.p.A and has held this role since October 2015. He joined Novartis in 2013 as Global Program Head for Gilenya, co-led the Gilenya GPT for two years and made stellar contributions to setting and executing an outstanding strategy for enhancing the benefit-risk for Gilenya. Danny has played a key role in shaping our overall MS strategy including the plans for CJM and the exploration of combination treatments in MS. Prior to Novartis, Danny had jobs of increasing responsibility in Innovative R&D and Medical Affairs at Teva Pharmaceutical Industries. Danny succeeds **Shreeram Aradhye** who was recently appointed Head of Global Medical Affairs and Chief Medical Officer for Novartis Pharmaceuticals. I'd like to thank Shreeram once again for his outstanding leadership of the

Neuroscience team these last few years.

Additionally, I also wanted to share with you that as part of harmonizing our terminology within the new GDD organization, our Development Franchises will be called Development Units. The terminology change does not have any impact on day-to-day operations in terms of partnering with the Business Franchises. Furthermore, within Oncology Development, the Global Program Heads will be called Franchise Global Program Heads to better align with the Oncology Business Unit set-up.

Please join me in congratulating Samit and Danny on their new positions and wishing them much success in their new roles.

Best regards,

Vas

